Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Oracle Stock: Is a Major Rally on the Horizon?

Dieter Jaworski by Dieter Jaworski
December 4, 2025
in AI & Quantum Computing, Analysis, Earnings, Nasdaq, Tech & Software
0
Oracle Stock
0
SHARES
12
VIEWS
Share on FacebookShare on Twitter

Ahead of its critical quarterly report, sentiment on Wall Street toward Oracle has undergone a dramatic shift. Following a period of volatility, prominent market analysts are now competing to issue bullish forecasts, suggesting a potential historic buying opportunity may have emerged. The recent pullback in the software giant’s shares is being framed not as a warning, but as a potential pause before its next major AI-driven surge.

The Bullish Case Gains Momentum

The renewed optimism stems from aggressive assessments by major financial institutions. Wells Fargo initiated coverage with an outright “Buy” rating and a price target of $280. The firm’s rationale centers on Oracle’s Cloud Infrastructure (OCI), which it argues occupies a unique niche in the AI ecosystem and is capturing significant market share due to its competitive price-performance advantages.

Even more optimistic is TD Cowen. Analyst Derrick Wood reaffirmed his “Buy” recommendation and maintained a staggering price target of $400. This projection implies an upside of nearly 95% from current levels. The consensus among these experts is clear: the correction from all-time highs represents a rare entry point rather than a signal for concern.

Should investors sell immediately? Or is it worth buying Oracle?

A $455 Billion Backlog of Confidence

This bullish outlook is supported by a fundamental metric that stands out in the industry: Oracle’s massive backlog of Remaining Performance Obligations (RPO). As reported in September, this figure reached an incredible $455 billion.

This number underscores the scale of long-term contracts Oracle has secured for training AI models. The company is also building tangible operational momentum. Confirmation came on Wednesday that its new flagship “Oracle AI Database 26ai” will be released for on-premise solutions in January 2026, setting a clear roadmap for the next major infrastructure upgrades for its largest enterprise clients.

All Eyes on the December Report

Investor attention is now intensely focused on the upcoming quarterly results scheduled for Tuesday, December 10. The key question will be the pace at which the company can convert its enormous order backlog into recognized revenue. From a technical perspective, the stock—which has declined approximately 17.5% over the last 30 days—is searching for a stable foundation after its recent sell-off. With analysts strongly advocating a “risk-on” approach, the current corrective phase could be nearing its end.

Ad

Oracle Stock: Buy or Sell?! New Oracle Analysis from February 8 delivers the answer:

The latest Oracle figures speak for themselves: Urgent action needed for Oracle investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Oracle: Buy or sell? Read more here...

Tags: Oracle
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Cassava Sciences Stock
Analysis

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

February 8, 2026
DroneShield Stock
Analysis

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock
Analysis

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Next Post
Teva Stock

Teva Shares Reach Unprecedented Peak Amid Strategic Shift

Walmart Stock

Walmart Shares Scale Unprecedented Heights

SentinelOne Stock

SentinelOne's Financial Report to Test AI Security Strategy

Recommended

Camping World Stock

Can Camping World Maintain Its Dividend Amid Market Pressures?

5 months ago
Trinity Biotech Stock

Trinity Biotech Faces Critical Nasdaq Compliance Deadline

5 months ago
DVY stock news

Amarin Strengthens Position and Maximizes Shareholder Value Through Share Repurchase Agreement with Cantor Fitzgerald

2 years ago
ASTeMobile Stock

ASTeMobile Shares Face Mounting Pressure as Investor Confidence Wanes

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Trending

Cassava Sciences Stock
Analysis

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

by Jackson Burston
February 8, 2026
0

The future of Cassava Sciences appears uncertain following the definitive termination of its Alzheimer's disease program. Detailed...

DroneShield Stock

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays
  • DroneShield Shares Face Headwinds Despite Record Performance
  • Rock Tech Lithium: Investors Await the Final Go-Ahead

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com